Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Anemia 55Neoplasms 27Leukemia 12Multiple Myeloma 11Lymphoma 9Neoplasms, Plasma Cell 8Lymphoma, Non-Hodgkin 7Leukemia, Lymphocytic, Chronic, B-Cell 7Breast Neoplasms 7Lymphoma, Follicular 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Precancerous Conditions 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Hodgkin Disease 5Waldenstrom Macroglobulinemia 4Myelodysplastic Syndromes 4Lymphoproliferative Disorders 4Fatigue 4Sezary Syndrome 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3Mycosis Fungoides 3Monoclonal Gammopathy of Undetermined Significance 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large-Cell, Anaplastic 3Lung Neoplasms 3Leukemia, Prolymphocytic 3

Interventions

Epoetin Alfa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Red-Cell Aplasia, Pure × Epoetin Alfa × Clear all
NCT00246597 2011-05-19

A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer

Ortho Biotech Products, L.P.

Phase 3 Terminated
37 enrolled
BreastClassical hematology

Anemia, Breast Neoplasms, Red-Cell Aplasia, Pure

Data powered by HemOnc (CC BY 4.0) Colophon âš¡